Клинические аспекты терапии семаглутидом: как выбрать оптимальный препарат?

1. McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025;31(10):3229–32.

PMID: 41039115. https://doi.org/10.1038/s41591-025-03765-w

2. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021;23 Suppl 3:5–29.

PMID: 34310013. https://doi.org/10.1111/dom.14496

3. Клинические рекомендации. Ожирение. Российская ассоциация эндокринологов, Общество бариатрических хирургов. Рубрикатор клинических рекомендаций Минздрава России. 2025. ID: 28_3. Доступ: https://cr.minzdrav.gov.ru/preview-cr/28_3 (дата обращения – 13.04.2026). (Clinical guidelines. Obesity. Russian Association of Endocrinologists, Society of Bariatric Surgeons. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2025. ID: 28_3. URL: https://cr.minzdrav.gov.ru/preview-cr/28_3 (date of access – 13.04.2026) (In Russ.)).

4. Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B et al. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–61.

PMID: 32441473. PMCID: PMC7318657. https://doi.org/10.1002/oby.22794

5. Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L et al; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.

PMID: 33667417. https://doi.org/10.1016/S0140-6736(21)00213-0

6. Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023;31(3):703–15.

PMID: 36655300. https://doi.org/10.1002/oby.23673

7. Amaro A, Skolnik NS, Sugimoto D. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022;134(sup1):18–27.

PMID: 36691308. https://doi.org/10.1080/00325481.2022.2147325

8. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26–36.

PMID: 40353578. https://doi.org/10.1056/NEJMoa2416394

9. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.

PMID: 37952131. https://doi.org/10.1056/NEJMoa2307563

10. Zhao Z, Song J, Faurby M, et al. Lower risk of MACE and all-cause death in patients initiated on semaglutide 2.4 mg in routine clinical care: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Moderated poster presentation presented at the American College of Cardiology Scientific Session & Expo. 2025; 29–31 March 2025. McCormick Place Convention Center, Chicago, US. Presentation 947-13.

11. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86.

PMID: 37363821. PMCID: PMC10653297. https://doi.org/10.1097/HEP.0000000000000520

12. Клинические рекомендации. Неалкогольная жировая болезнь печени. Российская ассоциация эндокринологов, Российская гастроэнтерологическая ассоциация, Общероссийская общественная организация «Российское научное медицинское общество терапевтов», Общероссийская общественная организация «Российская ассоциация геронтологов и гериатров», Российское общество по изучению печени, Российское общество профилактики неинфекционных заболеваний, Национальное общество профилактической кардиологии. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 748_2. Доступ: https://cr.minzdrav.gov.ru/view-cr/748_2 (дата обращения – 13.04.2026). (Clinical guidelines. Non-alcoholic fatty liver disease. Russian Association of Endocrinologists, Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Association of Gerontologists and Geriatricians, Russian Society for the Study of the Liver, Russian Society for the Prevention of Non-Communicable Diseases, National Society of Preventive Cardiology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 748_2. URL: https://cr.minzdrav.gov.ru/view-cr/748_2 (date of access – 13.04.2026) (In Russ.)).

13. Ng CH, Huang DQ, Nguyen MH. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. Clin Mol Hepatol. 2022;28(4):790–801.

PMID: 35545437. PMCID: PMC9597238. https://doi.org/10.3350/cmh.2022.0070

14. Emerging Risk Factors Collaboration; Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52–60.

PMID: 26151266. PMCID: PMC4664176. https://doi.org/10.1001/jama.2015.7008. Erratum in: JAMA. 2015 Sep 15;314(11):1179. Leening, Maarten (corrected to Leening, Maarten JG). PMID: 26151266. PMCID: PMC4664176. https://doi.org/10.1001/jama.2015.10410

15. Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73.

PMID: 28803953. https://doi.org/10.1016/j.jhep.2017.07.027

16. Rockey DC, Bell PD, Hill JA. Fibrosis – a common pathway to organ injury and failure. N Engl J Med. 2015;372(12):1138–49.

PMID: 25785971. https://doi.org/10.1056/NEJMra1300575

17. Phase 3 ESSENCE trial: Semaglutide in metabolic dysfunction associated steatohepatitis. Gastroenterol Hepatol (NY). 2024;20(12 Suppl 11):6–7. PMID: 39896971. PMCID: PMC11784563.

18. Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjær MS et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089–99.

PMID: 40305708. https://doi.org/10.1056/NEJMoa2413258

19. Дедов И.И., Шестакова М.В., Сухарева О.Ю., Мокрышева Н.Г., Андреева Е.Н., Безлепкина О.Б. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, О.Ю. Сухаревой. 12-й выпуск. Сахарный диабет. 2025;28(5S):1–175. (Dedov II, Shestakova MV, Sukhareva OYu, Mokrysheva NG, Andreeva EN, Bezlepkina OB et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Sukhareva OYu. 12th Edition. Sakharnyy diabet = Diabetes Mellitus. 2025;28(5S):1–175 (In Russ.)).

https://doi.org/10.14341/DM20255S

20. Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020;105(8):e2695–e2709.

PMID: 32442310. PMCID: PMC7457958. https://doi.org/10.1210/clinem/dgaa285

21. Клинические рекомендации. Синдром поликистозных яичников. Российская ассоциация эндокринологов, Российское общество акушеров-гинекологов. Рубрикатор клинических рекомендаций Минздрава России. 2025. ID: 910_1. Доступ: https://cr.minzdrav.gov.ru/view-cr/910_1 (дата обращения – 13.04.2026). (Clinical guidelines. Polycystic ovary syndrome. Russian Association of Endocrinologists, Russian Society of Obstetricians and Gynecologists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2025. ID: 910_1. URL: https://cr.minzdrav.gov.ru/view-cr/910_1 (date of access – 13.04.2026) (In Russ.)).

22. Шальнова С.А., Драпкина О.М. Значение исследования ЭССЕ-РФ для развития профилактики в России. Кардиоваскулярная терапия и профилактика. 2020;19(3):209–215. (Shalnova SA, Drapkina OМ. Contribution of the ESSE-RF study to preventive healthcare in Russia. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2020;19(3):209–215 (In Russ.)).

EDN: FJKWQQ. https://doi.org/10.15829/1728-8800-2020-2602

23. Tamer Erel C, Senturk LM. The impact of body mass index on assisted reproduction. Curr Opin Obstet Gynecol. 2009;21(3):228–35.

PMID: 19395966. https://doi.org/10.1097/GCO.0b013e32832aee96

24. Broughton DE, Moley KH. Obesity and female infertility: Potential mediators of obesity’s impact. Fertil Steril. 2017;107(4):840–47.

PMID: 28292619. https://doi.org/10.1016/j.fertnstert.2017.01.017

25. Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: An observational study. Front Endocrinol (Lausanne). 2014;5:140.

PMID: 25221543. PMCID: PMC4145240. https://doi.org/10.3389/fendo.2014.00140

26. Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV et al. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord. 2015;15:14.

PMID: 25880805. PMCID: PMC4389314. https://doi.org/10.1186/s12902-015-0005-6

27. Austregesilo de Athayde De Hollanda Morais B, Martins Prizao V, de Moura de Souza M, Ximenes Mendes B, Rodrigues Defante ML, Cosendey Martins O, Rodrigues AM. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. J Diabetes Complications. 2024;38(10):108834.

PMID: 39178623. https://doi.org/10.1016/j.jdiacomp.2024.108834

28. Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023;12(18):5921.

PMID: 37762862. PMCID: PMC10531549. https://doi.org/10.3390/jcm12185921

29. Jensterle M, Ferjan S, Janez A. The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: A 2-year observational study. Front Endocrinol (Lausanne). 2024;15:1366940.

PMID: 38665260. PMCID: PMC11043580. https://doi.org/10.3389/fendo.2024.1366940

30. Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349.

PMID: 39888616. PMCID: PMC11786232. https://doi.org/10.1001/jamanetworkopen.2024.57349

31. McLenon J, Rogers MAM. The fear of needles: A systematic review and meta-analysis. J Adv Nurs. 2019;75(1):30–42.

PMID: 30109720. https://doi.org/10.1111/jan.13818

32. European Medicines Agency. Questions and answers on benzyl alcohol used as an excipient in medicinal products for human use. 2017. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzyl-alcohol-used-excipient-medicinal-products-human-use_en.pdf (date of access – 13.04.2026).

33. Трошина Е.А., Анциферов М.Б., Аметов А.С., Галстян Г.Р., Маркова Т.Н., Романцова Т.И. с соавт. Персонифицированный подход к терапии ожирения на основе доказательных данных и клинических алгоритмов: семаглутид или тирзепатид. Проблемы эндокринологии. 2025;71(5):19–30. (Troshina EA, Antsiferov MB, Ametov AS, Galstyan GR, Markova TN, Romantsova TI et al. A personalized, evidence-based approach to obesity therapy using clinical algorithms: Semaglutide or tirzepatide. Problemy endokrinologii = Problems of Endocrinology. 2025;71(5):19–30 (In Russ.)).

EDN: TXGMRM. https://doi.org/10.14341/probl13677